Cite
Kendsersky NM, Lindsay J, Kolb EA, et al. The B7-H3-Targeting Antibody-Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models. Clin Cancer Res. 2021;27(10):2938-2946doi: 10.1158/1078-0432.CCR-20-4221.
Kendsersky, N. M., Lindsay, J., Kolb, E. A., Smith, M. A., Teicher, B. A., Erickson, S. W., Earley, E. J., Mosse, Y. P., Martinez, D., Pogoriler, J., Krytska, K., Patel, K., Groff, D., Tsang, M., Ghilu, S., Wang, Y., Seaman, S., Feng, Y., Croix, B. S., Gorlick, R., Kurmasheva, R., Houghton, P. J., & Maris, J. M. (2021). The B7-H3-Targeting Antibody-Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(10), 2938-2946. https://doi.org/10.1158/1078-0432.CCR-20-4221
Kendsersky, Nathan M, et al. "The B7-H3-Targeting Antibody-Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,10 (2021): 2938-2946. doi: https://doi.org/10.1158/1078-0432.CCR-20-4221
Kendsersky NM, Lindsay J, Kolb EA, Smith MA, Teicher BA, Erickson SW, Earley EJ, Mosse YP, Martinez D, Pogoriler J, Krytska K, Patel K, Groff D, Tsang M, Ghilu S, Wang Y, Seaman S, Feng Y, Croix BS, Gorlick R, Kurmasheva R, Houghton PJ, Maris JM. The B7-H3-Targeting Antibody-Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models. Clin Cancer Res. 2021 May 15;27(10):2938-2946. doi: 10.1158/1078-0432.CCR-20-4221. Epub 2021 Feb 22. PMID: 33619171; PMCID: PMC8127361.
Copy
Download .nbib